Abderrahmane Laadem
Daiichi Sankyo (United States)(US)
Publications by Year
Research Areas
Hemoglobinopathies and Related Disorders, Gastrointestinal Tumor Research and Treatment, Acute Myeloid Leukemia Research, Gastric Cancer Management and Outcomes, Myeloproliferative Neoplasms: Diagnosis and Treatment
Most-Cited Works
- → Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes(2020)527 cited
- → A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia(2020)292 cited
- → Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study(2017)286 cited
- → Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared With Allopurinol Alone—Results of a Multicenter Phase III Study(2010)195 cited
- → Sotatercept in patients with osteolytic lesions of multiple myeloma(2014)124 cited
- → Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia(2019)111 cited
- → Multiple‐dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA‐IgG1), a novel erythropoietic agent, in healthy postmenopausal women(2013)107 cited
- → Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study(2018)87 cited
- → A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia(2019)66 cited
- → Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies(2015)65 cited